Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalyst Pharm Inc
(NQ:
CPRX
)
16.49
+0.09 (+0.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
Next >
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
May 15, 2024
These two healthcare stocks may be deeply undervalued.
Via
The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
May 10, 2024
Via
Benzinga
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
May 08, 2024
The company doubled Wall Street's earnings views, but sales came in short.
Via
Investor's Business Daily
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
March 27, 2024
Via
Benzinga
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
March 07, 2024
Via
Benzinga
Earnings Preview For Catalyst Pharmaceuticals
February 27, 2024
Via
Benzinga
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Via
InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
March 10, 2024
While small-cap stocks can be incredibly risky, they also offer the potential for dramatic gains you won’t find with the big dogs.
Via
InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Via
Investor's Business Daily
Why Catalyst Pharmaceuticals Stock Is Trading Lower
January 05, 2024
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13% to $14.89 Friday morning.
Via
Benzinga
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
March 05, 2024
All three have exciting programs on the way.
Via
The Motley Fool
Top 3 Health Care Stocks You May Want To Dump In Q1
February 29, 2024
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months
January 22, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc.
Via
Benzinga
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances
January 18, 2024
With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
3 Biotech Stocks You Can Buy and Hold for the Next Decade
January 15, 2024
These companies are still in the early innings of their growth potential.
Via
The Motley Fool
Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024
January 14, 2024
With multiple drugs on the market and revenue ramping up, the sky's the limit.
Via
The Motley Fool
3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January
January 08, 2024
Small-cap stocks tend to outperform mid- and large-cap stocks over time and make for an important component of a balanced portfolio.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Shares of Applied Therapeutics, Inc.
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 05, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Amgen Stock Sees Relative Strength Rating Improve To 74
December 29, 2023
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.
Via
Investor's Business Daily
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
December 28, 2023
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.
Via
Investor's Business Daily
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
December 28, 2023
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81.
Via
Investor's Business Daily
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
December 26, 2023
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.
Via
Investor's Business Daily
Small Caps Are On A Tear Including Speculative Biotechs
December 26, 2023
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation.
Via
Talk Markets
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.